about
Guidelines for the use and interpretation of assays for monitoring autophagyA serine/arginine-rich nuclear matrix cyclophilin interacts with the C-terminal domain of RNA polymerase IIA mass spectrometric-derived cell surface protein atlasThe OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model.Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia.Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance.The clinical path to integrated genomics in ALL.Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenograftsIdentification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling.An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome.Image-based RNA interference screening reveals an individual dependence of acute lymphoblastic leukemia on stromal cysteine support.Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models.Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagyWhere can biology of childhood ALL be attacked by new compounds?Total body irradiation (TBI) in pediatric patients. A single-center experience after 30 years of low-dose rate irradiation.Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.From class waivers to precision medicine in paediatric oncology.Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway.CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results from Study AML-BFM 2004.Successful Salvage Chemotherapy with FOLFIRINOX for Recurrent Mixed Acinar Cell Carcinoma and Ductal Adenocarcinoma of the Pancreas in an Adolescent Patient.Reprogramming of B cell acute lymphoblastic leukemia cells: Do we need to shoot a moving target?Long non-stop reading frames on the antisense strand of heat shock protein 70 genes and prion protein (PrP) genes are conserved between species.Have chemosensitizing strategies for multidrug-resistant childhood acute lymphoblastic leukemia come of age?Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia.The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse.Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.Infection as a cause of childhood leukemia: virus detection employing whole genome sequencing.CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage.Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004.Humanised mouse models for haematopoiesis and infectious diseases.
P50
Q21996341-5C307522-6C33-4189-B19A-A7B7FD827E54Q24322515-F5A22360-41EF-4CA5-866D-2855E2F9E5ADQ28546580-FFC117B2-E636-4AA2-AD14-E6245137B374Q33383707-56FF4AF1-F322-4574-B6F0-DDE1FDDF30CAQ33746736-22247F03-DA56-4F78-B327-D2F42F9669CEQ33755338-8B4D7705-F91D-4181-A78A-4268AC8272CCQ34106773-261DAB35-6DD4-45ED-BFA0-DA2AF4C43022Q34135333-F9C4648B-26B5-4D3C-8300-F573F507429CQ34480244-14F1863D-A65E-445F-AA58-EC065CB13126Q34820210-A153C1A0-5234-4CD8-9FCE-C2041106EA6CQ34957024-CB30DB52-4789-478A-847D-D2E747E33863Q36154689-475DFD2B-34EB-419A-9550-9F37CDF8FFACQ36340868-484E5D3C-0754-4083-BA50-E5FF8C7ACC03Q37626910-39712CB4-A0E4-4467-8ACA-0D57DD8181BEQ37707635-D996A061-997E-443F-AB2E-D74460BC9771Q37808638-0467151F-C79D-4F39-8EE9-9358ED7D0156Q38185419-D55E88AB-EEA2-412C-9322-CD0E6373C004Q38643300-3A2ED00C-7728-4FE8-860B-518D42929446Q38693385-E1FD6301-447E-4006-B639-86E8318E0600Q38722012-C39BAA25-4D4A-4B09-BBCA-C9E61D87F39AQ38999126-60AF5E7A-8FE1-4420-AC15-59F4D8FFA144Q39031833-F90A5C27-AC25-4F40-A003-EF2D725894A0Q39766394-97742141-F989-4465-BC0C-B91AE9CA2772Q39876893-933186A3-7AF6-458E-A462-C693EA22D8B4Q40126040-9B4BA1FB-C95A-4C54-90E2-9D3828964307Q40204818-A02A20AD-FA37-414E-85C6-9DEC64F5D97AQ41731547-8FAE0BDC-5DA7-46D2-A671-2137AC4B3E93Q42055599-9669126C-E085-49F1-A2E2-4E10A9251F0BQ42332205-91D57BB1-426D-428C-ACB5-29AC69F5B528Q42672235-36A492E4-1CC8-47ED-8F59-09B5AA92180CQ42807400-2571EE81-3888-42B2-AFDC-F9375B93A39FQ42847773-6DF8651B-60AF-42DF-9AE3-688E9E9DBD76Q42923393-16289DC2-43F4-4F4A-A99D-E910271C67D6Q43973030-184BE519-74AE-44FE-B051-7D2C7A1B8D7DQ44586697-035C1972-6291-4A73-95EE-F37F95B7A503Q45330675-C58B7B19-C2D1-4B28-9ABC-6221BC0B54B1Q45891227-40B46EEA-8151-45BC-B4BA-BC3BAC1D3819Q46355702-13EE8B37-AEDD-4EFF-BFE9-39B8AF7ABEB6Q47157978-EB93EC6E-54C9-45B1-8FCC-EBAD9A5A7422Q47585444-2D69814A-4987-4B87-8545-9F141CBEBE5D
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0001-6571-6227
@en
name
Jean-Pierre Bourquin
@ast
Jean-Pierre Bourquin
@en
Jean-Pierre Bourquin
@es
Jean-Pierre Bourquin
@nl
type
label
Jean-Pierre Bourquin
@ast
Jean-Pierre Bourquin
@en
Jean-Pierre Bourquin
@es
Jean-Pierre Bourquin
@nl
prefLabel
Jean-Pierre Bourquin
@ast
Jean-Pierre Bourquin
@en
Jean-Pierre Bourquin
@es
Jean-Pierre Bourquin
@nl
P1053
C-2802-2011
P106
P21
P31
P496
0000-0001-6571-6227